Cellipont Bioservices announced a strategic collaboration with Soter Bio which will support integrated manufacturing pathways for complex cell therapy programs requiring coordinated biomolecule and cellular processing.
Under the collaboration, Cellipont will deliver GMP cell therapy manufacturing, analytical development, and regulatory execution from early clinical stages through late-stage supply. Soter Bio will provide complementary GMP RNA and biomolecule manufacturing capabilities that support upstream inputs for RNA-enabled cell engineering and next-generation therapeutic programs.
The collaboration is designed to help sponsors accelerate development timelines, reduce technical handoffs, and strengthen domestic manufacturing resilience for advanced therapeutic programs. This integrated, U.S.-based approach reflects growing industry momentum toward end-to-end biomanufacturing platforms that span RNA production through cell processing. Recent activity across the RNA ecosystem, including platform integrations and strategic partnerships by companies such as Quantoom Biosciences—highlights increasing demand for coordinated manufacturing solutions supporting RNA-based and cell therapy development.
"As cell therapies and RNA-enabled approaches become more technically integrated, early alignment across manufacturing stages is critical to de-risk development and move programs efficiently into the clinic," said Darren Head, CEO at Cellipont. "Our collaboration with Soter Bio strengthens the domestic manufacturing pathway and provides sponsors with a coordinated model from RNA and biomolecule supply through GMP cell therapy production."
"Soter Bio was built to support advanced therapeutic programs that depend on reliable, rapid, scalable input materials," said Mike Stewart, Founder and CEO of Soter Bio. "Partnering with Cellipont brings complementary GMP expertise to help sponsors navigate complex development programs while maintaining regulatory rigor and supply continuity."
The collaboration will support a broad range of applications, including investigational cell therapies and platform technologies across biotechnology, pharmaceutical, and government-sponsored programs. Both companies will continue operating independently while collaborating to support shared clients.